Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Process in drug discovery techniques
- Challenges in formulation development
- Pharmaceutical R&D: nanoparticles in industry
- Classification of organic nanocarriers
- Absorption enhancing effect of SLN
- Effect of particle size: Noyes-Whitney equation
- Effect of particle curvature
- Effect of particle size: rutin nanocrystals
- Effect of particle size in different conditions
- Nanocrystals production approaches
- Production approaches: bottom-up
- Production approaches: top-down
- Production approaches: combined methods
- Dapsone nanocrystals – wet bead milling
- Wet bead milling: small scale vs. pilot scale
- SN-38 nanocrystals – ultrasound reprecipitation
- SN-38 nanocrystals – cytostatic activity
- Meloxicam nanocrystals – ball milling (1)
- Meloxicam nanocrystals – ball milling (2)
- Meloxicam nanocrystals – pharmacokinetics
- Meloxicam nanocrystals – in vivo analgesia (male vs. female)
- Meloxicam nanocrystals – in vivo analgesia
- Nanocrystals in vivo performance
- Itraconazole nanocrystals - pharmacokinetics
- Marketed nanocrystals by top-down (1)
- Marketed nanocrystals by top-down (2)
- Marketed nanocrystals by top-down (IV route)
- Thank you
Topics Covered
- Process in drug discovery techniques
- Challenges in formulation development
- Pharmaceutical R&D: nanoparticles in industry
- Classification of organic nanocarriers
- Nanocrystals production approaches
- Wet bead milling
- Ball milling
- Nanocrystals in vivo performance
Talk Citation
Souto, E. (2024, July 31). Nanocrystals in drug delivery [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 5, 2024, from https://doi.org/10.69645/NPOY7507.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Eliana Souto has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Drug Delivery
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Eliana Souto,
and I was offered to talk about
the topic of nanocrystals
in drug delivery.
0:10
I would like to start by saying
that the process we have
been witnessing in
techniques that
currently support
drug discovery,
as happens with genomics,
proteomics, and high-throughput
screening methods, among others,
is resulting in an exponential
increase in the number of
potential candidates to be used
as active pharmaceutical
ingredients.
In rigor, a new drug candidate,
undergoes a time-consuming
development process,
and we still face a
shortage of examples of
these potential drugs actually
reaching Phase 1
clinical studies.
Within this scenario,
formulation development
becomes instrumental to ensure
that a potential
drug candidate is
bioavailable and reaches
the site of action.
0:57
Besides that, as
a number of physical
and chemical properties
of drugs are becoming
even more diversified,
and improved, with smart
drug delivery systems
with functional properties
are being proposed.
Most of the problems encountered
in formulation development are
attributed to: the
low water solubility
of potential drug candidates;
the low in vitro and
in vivo stability;
the reduced bioavailability as
a result of the limited
absorption of the tract;
the risk of systemic
distribution
requiring targeted delivery;
difficulties in being approved
by the regulatory authorities,
and also the difficulties in
scaling up of the
production process.